Managing Pregnancy Toxaemia in Goats: Therapeutic Response, Prognostic Indicators and Clinical Decision-Making

Pregnancy toxaemia presents one of the most challenging metabolic emergencies encountered in late-gestation does. Although treatment aims to correct the negative energy balance and stabilize the animal, clinical outcome depends largely on the severity of disease at presentation. Once neurological signs develop and fetal viability is compromised, prognosis becomes guarded despite intensive medical management¹. Clinical observations from the evaluated cases provide important guidance on treatment response, prognostic indicators and timely decision-making that can assist practicing veterinarians managing pregnancy toxaemia in the field. 

Initiating Therapy at the Right Stage¹ 

Affected does received intravenous 5% dextrose as the primary treatment, supported with parenteral administration of Vitamins B1, B6 and B12. Oral glycerine was administered at 25 ml twice daily as an additional energy source. Treatment response was monitored through improvement in clinical signs together with changes in haematological, biochemical, metabolic and hormonal parameters. 

The clinical outcomes clearly demonstrated that initiating therapy during the early stages of disease resulted in a markedly better response than treating advanced cases. 

Assessing Prognosis During Clinical Management 

Clinical examination remained central to evaluating prognosis. Does that continued to stand and exhibited mild clinical signs generally responded more favourably to treatment than animals presenting with neurological abnormalities. 

As disease severity increased, affected does developed stargazing, sternal recumbency, and lateral deviation of the neck. These findings were frequently accompanied by markedly elevated blood β-hydroxybutyric acid (BHBA) concentrations, indicating advanced metabolic compromise¹. 

Blood glucose concentration also proved to be an important prognostic indicator. While hypoglycaemia was commonly observed during pregnancy toxaemia due to reduced gluconeogenesis and increased fetal glucose demand¹, clinical observations showed that hyperglycaemia in advanced pregnancy toxaemia indicated fetal death². In does that were more than 140 days pregnant, absent fetal heartbeats on ultrasonography were associated with BHBA concentrations exceeding 7 mmol/L together with abnormally elevated blood glucose concentrations. This finding was attributed to removal of the suppressive effect of the fetus on hepatic gluconeogenesis or increased serum cortisol concentrations^1,2. 

Clinical Outcomes: What the Cases Demonstrated¹ 

The difference in treatment response between subclinical and clinical disease was striking. 

All twelve subclinical cases recovered completely following therapy, resulting in a 100% cure rate. In contrast, among the twelve clinically affected does, only four recovered, producing a 33% cure rate. 

Clinical observations further demonstrated that prognosis varied within the clinical group. Does with BHBA concentrations ranging from 2.1 to 3.5 mmol/L, which remained standing and exhibited anorexia, dullness and bruxism, showed improved alertness and feed intake from the third day of treatment and eventually recovered. 

Conversely, does with BHBA concentrations of 5.2 mmol/L and 6.7 mmol/L, presenting with sternal recumbency and weak fetal heartbeats, failed to respond despite treatment and died. Animals with BHBA concentrations above 7 mmol/L, accompanied by hyperglycaemia and absent fetal heartbeats, had the poorest prognosis. These clinical observations highlight the importance of interpreting laboratory findings alongside physical examination and fetal assessment. 

When Medical Therapy May Not Be Enough 

Clinical findings indicated that medical treatment alone may not be sufficient in advanced pregnancy toxaemia. When fetal death was confirmed or animals failed to respond to supportive therapy because of persistent fetal glucose demand or advanced disease, induction of parturition or caesarean section became important management options to improve the chances of saving the dam^2,3. 

Ultrasonography therefore played a dual role by confirming gestational stage and assessing fetal viability, allowing veterinarians to make timely decisions regarding continued medical treatment or obstetrical intervention¹. 

Practical Clinical Insights 

• Begin treatment immediately after diagnosis, as therapeutic response declines with disease progression. 

• Monitor BHBA and blood glucose concentrations throughout treatment to assess disease severity and prognosis. 

• Unexpected hyperglycaemia in an advanced clinical case should raise suspicion of fetal death. 

• Evaluate fetal viability using ultrasonography before making treatment decisions. 

• Does presenting with sternal recumbency, lateral deviation of the neck and markedly elevated BHBA concentrations should be considered to have a guarded prognosis. 

• Consider induction of parturition or caesarean section when fetal death is confirmed, or advanced cases fail to improve with medical therapy. 

The clinical outcomes demonstrated that the stage of disease at presentation has a profound influence on treatment success. Early therapeutic intervention resulted in complete recovery of all subclinical cases, whereas advanced clinical disease carried substantially poorer outcomes. Integrating clinical examination with BHBA estimation, blood glucose monitoring and assessment of fetal viability enables veterinarians to make timely, evidence-informed decisions while managing pregnancy toxaemia in goats. 

References 

1. Vijayanand V, Balagangatharathilagar M, Gnanaraj PT, Vairamuthu S. Diagnostic indicators and therapeutic evaluation of pregnancy toxaemia in goats. Indian J. Anim. Res. 2022 Apr 1;56:451-9. https://arccjournals.com/journal/indian-journal-of-animal-research/B-4456 

2. Lima MS, Pascoal RA, Stilwell GT. Glycaemia as a sign of the viability of the foetuses in the last days of gestation in dairy goats with pregnancy toxaemia. Irish veterinary journal. 2012 Jan 23;65(1):1. https://link.springer.com/content/pdf/10.1186/2046-0481-65-1.pdf 

3. Brounts SH, Hawkins JF, Baird AN, Glickman LT. Outcome and subsequent fertility of sheep and goats undergoing cesarean section because of dystocia: 110 cases (1981–2001). Journal of the American Veterinary Medical Association. 2004 Jan 15;224(2):275-81. https://www.researchgate.net/profile/Sabrina-Brounts/publication/8909259